Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cyclin imide peptidyl metalloprotease inhibitor and its application

A peptide compound, trimethoxyaniline-based technology, used in cyclic imide peptide metalloproteinase inhibitors and their application fields, can solve the problem of relatively sensitive enzymatic degradation, poor member selectivity, and weakened recognition and killing of tumor cells. abilities, etc.

Inactive Publication Date: 2007-06-06
SHANDONG UNIV
View PDF2 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2) APN is abundantly expressed on the surface of granulocytes and lymphocytes, and is also involved in T lymphocyte-dependent inflammatory responses; it can also be expressed on the surface of antigen-presenting cells to degrade immune active substances (such as interleukin-8); it is involved in antigen processing and The major histocompatibility complex type II (MHC-II) adhesion epitope on the cell surface depends on the recognition of antigens by T cells, which reduces the recognition ability of T cells and at the same time weakens the ability of macrophages and NK cells to tumor The ability to identify and kill cells reduces the body's immunity
[0009] Since the 1990s, many MMPs inhibitors have been developed, most of which are peptides or peptide analogs, which are more sensitive to enzymatic degradation. In addition, because most of them have long-chain structures and contain a large number of rotatable single bonds, they are not suitable for MMPs. Members of the same family have poor selectivity, which is why most MMPs inhibitors are shot down in the clinical stage
In addition, most of the inhibitors against APN are natural products. The only drug on the market, Ubenimex, has a dipeptide-like structure containing β-amino acids. It is currently used as an immune enhancer for the treatment of leukemia. Isolated from the culture fluid of Streptomycesolivorecticuli, the source is limited
The metalloprotease inhibitors reported in the current literature do not take into account the selectivity of the two (endopeptidase and exopeptidase), so there is no in-depth discussion on the mechanism of action

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclin imide peptidyl metalloprotease inhibitor and its application
  • Cyclin imide peptidyl metalloprotease inhibitor and its application
  • Cyclin imide peptidyl metalloprotease inhibitor and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1. Preparation of (S)-2-(3,4,5-trimethoxyanilino)glutaric acid (4)

[0094] 1) 3,4,5-Trimethoxybenzoic acid (2). Dissolve NaOH (80g, 2mol) in 500ml distilled water, cool to room temperature, add 3,4,5-trihydroxybenzoic acid (gallic acid, 50g, 0.294mol), immediately stopper, stir until dissolved. Control the internal temperature below 20°C, add (CH 3 ) 2 SO 4 (89g, 67ml, 0.71mol), at this time the temperature can rise to 30-45°C, open the cork from time to time to deflate. After 20min, add the second batch of equal amount of (CH 3 ) 2 SO 4 At this time, the temperature can rise to 40-45°C, stir for 10 minutes, heat up and boil for 2 hours. Then add 50g of 40% NaOH solution and boil for 2h to saponify the ester that may be generated. The reaction solution was cooled to room temperature, acidified with dilute hydrochloric acid, filtered with suction, and the filter cake was washed with cold water to obtain 48 g of crude product.

[0095] Crude refinement. ...

Embodiment 2

[0098] Example 2. Preparation of (S)-2-(2,6-dioxo-3-(3,4,5-trimethoxybenzamido)piperidin-1-yl)acetic acid (6)

[0099] 1) (S)-N-(2,6-Dioxy-tetrahydro-2H-pyran-3-yl)-3,4,5-trimethoxybenzamide (5). 3,4,5-trimethoxybenzoylglutamic acid (10g, 2.9mmol), add 80ml of acetic anhydride, and keep warm in an oil bath at 55-60°C for 5h. Remove the insoluble matter by filtration while hot, add an appropriate amount of anhydrous ether, cool, and precipitate a white solid. 5.2 g was weighed by filtration, yield 55%, mp 150-152°C. IR (KBr, cm-1): 3310.0, 2945.1, 1777.0, 1640.7, 1504.2, 1239.6, 1129.6; ESI-MS: m / z 323.8.

[0100] 2) (S)-2-(2,6-Dioxy-3-(3,4,5-trimethoxybenzamido)piperidin-1-yl)acetic acid (6). Compound 5 (5.0 g) was dissolved in 50 ml of DMF, 1.0 g of glycine was ground and added to DMF, and heated at 110° C. for 5 hours. The mixture was cooled to room temperature, poured into an equal volume of ice water with a pH of 2, and left overnight, a large amount of white crystals ...

Embodiment 3

[0101] Example 3. (S)-Methyl-2-(2-(2,6-dioxo-3-(3,4,5-trimethoxyanilino)piperidin-1-yl)acetamido) Preparation of Acetate (7a).

[0102] Compound 6 (1.90g, 5mmol) and HoBt (0.81g, 6mmol) were dissolved in 20ml of dichloromethane and 2ml of dimethyl sulfoxide, cooled to 0°C in an ice bath, and slowly added dropwise with EDCI (1.44g, 7.5mmol). Chloromethane solution was added dropwise in about 1 hour, then removed from the ice bath and stirred for 2 hours. Glycine methyl ester hydrochloride (0.75 g, 6 mmol) was added in batches in an ice bath, and the pH value was adjusted to 7 with triethylamine. After the ice cubes melted automatically, the stirring was continued overnight. The reaction liquid was successively washed with 1N hydrochloric acid, 1% sodium carbonate, saturated brine, dried over sodium sulfate, and purified by column chromatography to obtain the final product with a yield of 79%. mp98.7-100.6℃. 1 HNMR (400MHz, DMSO-d6, ppm): δ9.04(t, 1H), 8.88(d, 1H), 7.17(s, 2H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides one kind of powerful peptide-like metalloprotease inhibitor, which exhibits obvious selectivity between endopeptidase and exopeptidase and may be used in treating diseases with abnormal active expression of metalloprotease effectively. Specifically, the present invention relates to the peptide-like compound in the general expression as shown, and its optical isomers, pharmaceutically acceptable salts, solvates and medicine precursor. The present invention also relates to the medicine composition containing the peptide-like compound and its medicinal use.

Description

technical field [0001] The present invention relates to a preparation method, an activity test, a composition containing the peptidoid compound and the application of a class of peptidoid compound selectively inhibiting metalloprotease with a cyclic imide peptidoid skeleton. Background technique [0002] 1. Matrix metalloproteinases (MMPs) [0003] MMPs are a class of endopeptidases dependent on calcium ions and zinc ions. The activity of MMPs is strictly controlled by the expression level of genes and the secretion level of zymogen activators / inhibitors. MMPs play an important role in the degradation of extracellular matrix and tissue reconstruction. In many pathological processes, such as arthritis, tissue ulceration, growth and metastasis of malignant tumors, MMPs also play an important role. [0004] At present, 28 members of the MMPs family have been found in mammals (Szabo, K.A. et al. Clinical and Applied Immunology Reviews. 2004, 4, 295), which are divided into dif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D211/88C07K5/06A61K31/4412A61P35/00
Inventor 徐文方李乾斌
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com